Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation Meeting Abstract
| Authors: | Mato, A. R.; Svoboda, J.; Luning Prak, E. T.; Schuster, S. J.; Tsao, P. Y.; Dorsey, C.; Sarmasti, L. M.; Becker, P. S.; Brander, D. M.; Nasta, S.; Landsburg, D. J.; King, C. M.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A. D.; Purdom, M.; Paskalis, D.; Sportelli, P.; Miskin, H. P.; Weiss, M. S.; Shadman, M. |
| Abstract Title: | Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 119 |
| End Page: | 120 |
| Language: | English |
| ACCESSION: | 136932851 |
| DOI: | 10.1002/hon.79_2629 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting abstract: O73 -- Source: cin20 |
Altmetric
Citation Impact
BMJ Impact Analytics
